Curcumin-containing composition, methods of making, and methods of using

• US 20080031980A1
• Filed: 08/02/2006
• Published: 02/07/2008
• Est. Priority Date: 08/02/2006
• Status: Abandoned Application

• Current Assignee: FARR Laboratories LLC
• Original Assignee: FARR Laboratories LLC
• Inventors: Shoskes, Daniel, Rodriguez, Al
• Application Number:
  US11/497,319
• Publication Number:
  US 20080031980A1
• Time in Patent Office: Days
• US Class Current: 424/773
• CPC Class Codes: A61K 36/9066 Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives

Abstract

A composition includes 50-80 wt. % of at least one curcumin compound, 10-50 wt. % quercetin, ≧3 wt. % papain, and ≧3 wt. % bromelain, wherein the composition is suitable for oral administration to a human. Methods of making and using the composition are provided.

Claims

1. A composition, comprising:

50-80 wt. % of at least one curcumin compound;

10-50 wt. % quercetin;

≧

3 wt. % papain; and

≧

3 wt. % bromelain;

wherein the composition is suitable for oral administration to a human.

2. The composition of claim 1, wherein the curcumin compound is selected from the group consisting of bisdemethoxycurcumin, demethoxycurcumin, curcumin, dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, octahydrocurcumin, diacetylcurcumin, p, p dihydroxydicinnamoylmethane, hexahydrocurcuminol, curcumin glucuronide, curcumin sulfate, [6]-paradol, dihydrocapsaicin, salicylcurcuminoid, monomethylcurcumin, trimethylcurcumin, 1,7-bis(3,4-dihydroxyphenyl)-11,6-heptadiene-3,5-dione, p-dyhydroxydicinamoyl feruloyl methane, capsaicin, [6]-gingerol, cassumunin A, cassumunin B, yakuchinone A, yakuchinone B, isoeugenol, dibenzoylmethane, rosmarinic acid, 2-hydroxydibenzoylmethane, hydrazinocurcumin, hydrazinodemethoxycurcumin, hydrazinobisdemethoxycurcumin, hydrazinobenzoyldemethoxycurcmin, and a combination thereof.

3. The composition of claim 1, wherein the curcumin compound is selected from the group consisting of bisdemethoxycurcumin, demethoxycurcumin, curcumin, and a combination thereof.

4. The composition of claim 1, which comprises about 60-70 wt. % of the curcumin compound.

5. The composition of claim 1, which comprises about 65 wt. % of the curcumin compound.

6. The composition of claim 1, wherein the curcumin compound is a combination of bisdemethoxycurcumin, demethoxycurcumin, and curcumin.

7. The composition of claim 1, which comprises about 15-45 wt. % quercetin.

8. The composition of claim 1, which comprises about 25-40 wt. % quercetin.

9. The composition of claim 1, which comprises about 25-30 wt. % quercetin.

10. The composition of claim 1, which comprises about 3.1-20 wt. % papain.

11. The composition of claim 1, which comprises about 3.1-5.1 wt. % papain.

12. The composition of claim 1, which comprises about 3.1-10 wt. % bromelain.

13. The composition of claim 1, which comprises about 3.1-5.1 wt. % bromelain.

14. The composition of claim 1, further comprising one or more selected from the group consisting of cranberry, green tea extract, black cohosh, wood betony, passion flower, valerian root, saw palmetto, zinc, calcium, and a combination thereof.

15. The composition of claim 1, further comprising a sustained release coating.

18. A method for treating one or more selected from the group consisting of chronic nonbacterial prostatitis, chronic pelvic pain syndrome, overactive bladder, sexual dysfunction, prostatitis, prostatodynia, urinary incontinence, pain during intercourse, genitourinary pain not associated with infection, bladder pain, abdominable pain, urinary frequency, category III chronic prostatitis syndrome, category IIIa chronic pelvic pain syndrome, category IIIb chronic pelvic pain syndrome, chronic voiding symptoms not associated with infection, adverse side effects associated with renal transplantation, protection against kidney damage associated with the administration of aminoglycosides, delayed graft function in kidney transplant patient, acute rejection in kidney transplant patient, drug induced neuropathy in kidney transplant patient, drug induced tremor in kidney transplant patient, chronic allograft nephropathy in kidney transplant patient, post-transplant risk of colon cancer in kidney transplant patient, post-transplant risk of prostate cancer in kidney transplant patient, protection against kidney damage from intravenous contrast dye, protection against ischemic kidney damage from trauma or surgery, hypercholesterolaemia, high LDL cholesterol level, and a combination thereof, comprising administering the composition of claim 1 to a human.

16. A method, comprising contacting:

50-80 wt. % of at least one curcumin compound;

10-50 wt. % quercetin;

≧

3 wt. % papain; and

≧

3 wt. % bromelain;

to form a composition suitable for oral administration to a human.

17. The method of claim 16, wherein the composition is in the form of a capsule.